𝔖 Bobbio Scriptorium

✦ LIBER ✦

Reduced Uptake of FDOPA PET in End-stage Liver Disease With Elevated Manganese Levels

✍ Scribed by Criswell, S. R.; Perlmutter, J. S.; Crippin, J. S.; Videen, T. O.; Moerlein, S. M.; Flores, H. P.; Birke, A. M.; Racette, B. A.

Book ID: 115469763
Publisher: American Medical Association
Year: 2012
Tongue: English
Weight: 184 KB
Volume: 69
Category: Article
ISSN: 0003-9942
DOI: 10.1001/archneurol.2011.771

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Elevated plasma and urine levels of ADMA

Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2α in end-stage liver disease

✍ Dimitrios Tsikas; Iris Rode; Thomas Becker; Björn Nashan; Jürgen Klempnauer; Jür 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

Uptake of hepatitis C antibody testing i

Uptake of hepatitis C antibody testing in patients with end-stage liver disease in Glasgow, 1993–2007

✍ S. A. McDonald; S. J. Hutchinson; S. Cameron; S. M. Bird; P. R. Mills; A. McLeod 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB

274 THE CRP LEVEL IS A GOOD PREDICTOR OF

274 THE CRP LEVEL IS A GOOD PREDICTOR OF MORTALITY INDEPENDENT OF PUGH OR MELD SCORES IN PATIENTS WITH END STAGE LIVER DISEASE (ESLD)

✍ O. Barbot; J.P. Cervoni; T. Thevenot; C. Richou; C. Vanlemmens; V. Di Martino 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Is there an association between elevated

Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis

✍ Jaime L Natoli, Rob Boer, Brian H Nathanson, Ross M Miller… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 376 KB

444 Comparison of serum CA 19-9, CEA and

444 Comparison of serum CA 19-9, CEA and AFP levels in patients with end stage liver disease (ESLD) with or without ascites vs healthy controls—A retrospective study

✍ Chhaya Hasyagar; Savant Mehta 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

Protective antibody levels and dose requ

Protective antibody levels and dose requirements of IV 5% Nabi hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B induced end stage liver disease: Rolland C Dickson, Mayo Clinic Jacksonville, Jacksonville, FL; Nora Terrault, University of California at San Francisco, San Francisco, CA; Michael B Ishitani, Mayo Clinic Rochester, Rochester, MN; Rajender Reddy, University of Miami, Miami, FL; Patricia Sheiner, Mt Sinai, New York, NY; Velimir Luketic, Medical College of Virginia, Richmond, VA; Terrence Angtuaco, Rush Presbyterian-St Lukes Medical Center, Chicao, IL; Consuelo Soldevilla-Pico, University of Florida, Gainesville, FL; Michael W Fried, University of North Carolina, Chapel Hill, NC; Robert Brown Jr., Columbia Presbyterian Medical Center, New York, NY; Anna S Lok, University of Michigan, Ann Arbor, MI; Janet Johnson, Nabi, Rockville, MD

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB